Sign in
Not yet recruitingNo phase

Intranasal Dexmedetomidine Combined With Esketamine for Emergence Quality After Suspension Laryngoscopy

Key facts

Who runs it
The First Hospital of Jilin University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
134 people, planned
Started
Sept 2026
Expected to end
Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dexmedetomidin
  • Esketamine
Record updated
19 October 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • 1. Aged 18-65 years, male or female. 2. ASA physical status Ⅰ or Ⅱ. 3. Scheduled for elective surgery under general anesthesia with tracheal intubation; Expected operation duration 30-180 minutes. 5. Able to understand the study content and sign written informed consent voluntarily

Who cannot take part

  • 1. Preoperative cognitive dysfunction or psychiatric disorders. 2. Known allergy to dexmedetomidine or esketamine. 3. Severe cardiac, respiratory, hepatic or renal insufficiency. 4. Predicted difficult airway. 5. Drug abuse or long-term use of sedatives. 6. Pregnant or breastfeeding women

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a single-center, prospective, single-blinded, randomized controlled trial conducted at The First Hospital of Jilin University. A total of 134 adult patients aged 18-65 years with ASA Ⅰ-Ⅲ undergoing elective laryngoscopic surgery for vocal cord polyps will be enrolled. Subjects will be randomly assigned into two groups. The control group receives intranasal dexmedetomidine plus intravenous normal saline before anesthesia induction. The combination group receives the same dose of intranasal dexmedetomidine plus intravenous esketamine before induction. The primary objective is to compare the incidence of emergence agitation within 60 minutes after extubation. Secondary outcomes include hemodynamic changes, adverse events, recovery time, PACU stay, postoperative sore throat pain and quality of recovery at 24 hours. Standardized anesthesia induction and maintenance will be applied for all patients. The study aims to explore whether the combination of intranasal dexmedetomidine and esketamine improves recovery quality in patients undergoing suspension laryngoscopy.

The 2 groups in the trial

  • Control GroupExisting treatment, for comparison

    Patients receive dexmedetomidine before anesthesia induction.

    Treatment: Dexmedetomidin

  • Intervention GropTreatment being tested

    Patients receive dexmedetomidine combined with esketamine before anesthesia induction.

    Treatment: Dexmedetomidin and Esketamine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Dexmedetomidine Nasal Spray Combined With Esketamine on the Quality of Recovery in Patients Undergoing Suspension Laryngoscopy Surgery
Criteria questions
Built from NCT07880938, who can take part
Record updated
19 October 2026